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Abstract
Background: Myotonic Dystrophy is the most common form of muscular dystrophy in adults, affecting an estimated
10 per 100,000 people. It is a multisystemic disorder affecting multiple generations with increasing severity. There are
currently no licenced therapies to reverse, slow down or cure its symptoms. In 2009 TREAT-NMD (a global alliance with
the mission of improving trial readiness for neuromuscular diseases) and the Marigold Foundation held a workshop of
key opinion leaders to agree a minimal dataset for patient registries in myotonic dystrophy. Eight years after
this workshop, we surveyed 22 registries collecting information on myotonic dystrophy patients to assess the
proliferation and utility the dataset agreed in 2009. These registries represent over 10,000 myotonic dystrophy
patients worldwide (Europe, North America, Asia and Oceania).
Results: The registries use a variety of data collection methods (e.g. online patient surveys or clinician led)
and have a variety of budgets (from being run by volunteers to annual budgets over €200,000). All registries
collect at least some of the originally agreed data items, and a number of additional items have been suggested in
particular items on cognitive impact.
Conclusions: The community should consider how to maximise this collective resource in future therapeutic programmes.
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Background
Patient Registries have the different objectives that include:
[1] improve the understanding of the prevalence, natural
history, pathogenesis, and treatment options of diseases
in recognition by a systematic collection of clinical and
demographic data; [2] set up an infrastructure that allows
collaboration between patients, health and care providers,
academia (research) and industry; and, [3] obtain a picture
of the targeted cohort’s real-life disease burden, standards
of care and patient’s preferences towards treatment [1–3].
In rare diseases such as Myotonic Dystrophy (DM),
Disease-specific Patient Registries have been recognised
as indispensable tools to translate clinical and research
knowledge into therapeutic solutions [1, 4–6]. DM is a
genetically caused neuromuscular condition estimated to
affect 10 per 100,000 people in European populations [7, 8].
It is found in two forms: myotonic dystrophy type 1 (DM1)
and the less frequent myotonic dystrophy type two (DM2).
DM1 is one of the most variable human diseases with a
complex multisystemic presentation. The condition is char-
acterised by progressive muscle wasting and myotonia;
however, it also has significant impact on cognition cardiac,
visual, endocrine, gastrointestinal, and pulmonary systems.
These manifestations have a significant effect impact on
social participation and quality of life [9–13] . There are
currently limited therapies for certain symptoms, and none
to slow down, reverse or cure the disease. As with all rare
diseases, the need to coordinate resources and knowledge
is essential in order to move towards larger and more suc-
cessful clinical trials and ultimately better management.
The International Rare Diseases Research Consortium
(IRDiRC) advocates for a global collaboration between dif-
ferent disease specific registries collecting a minimum set
of standardised and consistent data that will boost research
at all levels [14]. In 2009, a group of key opinion leaders
agreed upon a minimal core dataset for DM patient regis-
tries. This dataset was agreed at a TREAT-NMD/Marigold
workshop held in Naarden, Netherlands and has since been
referred to as the “Naarden” dataset [15, 16]. Since then a
unified global registry for DM, using a federated or centra-
lised model has not been fully established. However, an
increasing number of registries are collecting what was
agreed as essential data on myotonic dystrophy. Here we
present a summary of the global experience of designing
and setting up these registries. We aim to describe the
current landscape of DM registries and to assess how
widely used the Naarden dataset is and its perceived
usefulness or shortcomings.
Methods
Through the platforms of TREAT-NMD (global alliance
with the mission of improving trial readiness in neuro-
muscular diseases) and the Marigold Foundation (a re-
search foundation DM-specific who commissioned this
report), 25 registries were identified worldwide and in-
vited to participate (Fig. 1). All registries were invited to
complete an online survey asking about the design, set
up, and utility of the registry. The original data was col-
lection period was between September and December
2015, with updates provided in April 2017. This survey
can be found in the Additional file 1.
Results
Of these 25 registries, 21 were currently active, two had
recently launched and two were still in set up phase.
Twenty-two registries responded to this request, and it
is this information that is described here.
Collectively these registries contain information on over
10,000 DM patients worldwide (Table 1). The longest
standing registry is the “National Registry for Myotonic
Dystrophy and Facioscapulohumeral Muscular Dystrophy
Patients and Family Members” based at the University of
Rochester, USA which started collecting data in 2000 [17].
A further six registries/databases were established before
the publication of the original Naarden dataset (CRAMP,
Genemu, BNMDR and DM-SCOPE and the registries in
Serbia and Bulgaria). In the years since this workshop,
an additional 15 registries collecting data on DM patients
have been launched.
In many cases registries are collecting information on
both DM1 and DM2. Across the registries surveyed, the
majority of records (86%) related to DM1 patients. How-
ever, there are some notable exceptions to this only 40%
of patients in the German registry have DM1, and 51%
in ReaDY (Czech Republic). A larger proportion of DM2
patients are also present in Akhenaten (Serbia) and
REMUDY (Japan) where 33% and 20% of registered
patients have DM2.
Mandatory and highly encouraged items
The mandatory and highly encouraged items from the
“Naarden” dataset collected by each registry are sum-
marised in Table 2. All registries collected at least 50%
of the mandatory items as listed in the original core
dataset with 13 (59%) collecting all of these mandatory
items. Eight (36%) registries collected all of the mandatory
and highly encouraged items. Two of the registries set up
before the publication of the Naarden dataset (Genemu
and the Bulgarian registry) already collected all of the
mandatory data items. Ten of the 15 registries launched
after the publication of the Naarden dataset collect all of
these items.
Only 12 (55%) of the 22 registries surveyed asked partic-
ipants whether they were signed up to another registry to
determine if there are duplicate registrations. Registry
owners were asked which items they would consider re-
moving from the original core dataset, two registry cura-
tors answered that ethnic origin was not essential, two
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Fig. 1 Location of registries collecting data on myotonic dystrophy. The countries shaded with stripes are in the set up phase of registries
Table 1 Numbers of patients registered across countries as provided in April 2017
Name of Registry Country Year established DM1 > 18 DM1 < 18 DM2 > 18 DM2 < 18
National Registry for Myotonic Dystrophy and
Facioscapulohumeral Muscular Dystrophy Patients
and Family Members
USA 2000 1177 67 214 0
CRAMPS Netherlands 2001 452 0 30 0
Genemu** Quebec, Canada 2005 N/A N/A N/A N/A
Belgian Neuromuscular Disease Registry Belgium 2008 493 34 16 2
DM-SCOPE France 2008 2203 255 107 0
Bulgarian Myotonic Dystrophy Registry Bulgaria 2009 76 2 6 0
Akhenaten, Serbian Registry for Myotonic Dystrophies Serbia 2009 335 0 86 0
Polish Registry of Neuromuscular Patients Poland 2010 246 7 125 0
ReaDY Myotonic Disorders Czech Republic 2011 184 5 286 2
Canadian Neuromuscular Disease Registry Canada 2011 188 21 38 0
New Zealand Neuromuscular Disease Registry New Zealand 2011 156 11 11 0
Myotonic Dystrophy Patient Registry for Germany
and Switzerland
Germany and Switzerland 2012 243 16 246 3
UK Myotonic Dystrophy Patient Registry UK 2012 429 45 16 0
China DM Registry China 2012 61 8 0 0
Spanish Registry of neuromuscular diseases Spain 2012 265 6 7 0
Egyptian neuromuscular registry Egypt 2013 4 6 5 3
The Italian registry for Myotonic Dystrophy Italy 2013 491 16 31 0
Myotonic Dystrophy Family Registry* USA 2013 1051* 250*
NMiS Sweden 2013 194 17 0 0
Registry of Muscular Dystrophy REMUDY Japan 2014 554 45 1 0
Ukrainian registry of muscular dystrophies Ukraine Not provided 3 1 0 0
Australian Myotonic Dystrophy Registry*** Australia Data collection has
not yet begun
0 0 0 0
Totals 9156 1485
Total registered globally 10,641
*Estimates based on literature review. **Recent numbers not available. ***Data collection not yet begun
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Table 2 Proliferation of the core “Naarden” dataset for myotonic dystrophy registries
“X” indicates the item is collected. The highlighted data items those listed as mandatory in the Naarden dataset. The shading indicates that these items are not
collected by the registry
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suggested the removal of ECG and echocardiogram results
and two suggested that the date and method used for gen-
etic testing should be removed.
Along with the core dataset, many registries collect add-
itional information about myotonic dystrophy patients;
some registries use additional validated questionnaires re-
lating to pain (McGill, BI, NSPI), fatigue (ESS, FDSS) and
quality of life (SF36, InQoL, EQ. 5D and ActivLim). In
addition, some registries collect data regarding the gastro-
intestinal and central nervous systems and anthropomet-
ric measurements. Several registries also include detailed
socioeconomic data. However, there was no standardisa-
tion or commonality among these items.
Purpose and utility of the registries
The registries and databases contacted were asked to rank
10 possible purposes of registries in order of importance.
The most common purpose was for recruitment into clin-
ical research both for therapeutic and observational stud-
ies. Providing feasibility data to researchers and improving
standards of care were also among top priorities. Asses-
sing disease prevalence and analysis of disease progression
were less often the main purpose (Fig. 2).
Thirteen (59%) of the 22 registries reported having
supported recruitment into clinical research, 11 had pro-
vided feasibility data for use in planning of a trial and 13
reported entering recruitment of patients to questionnaire
based studies. Eleven (50%) of the registries had contrib-
uted to publications in scientific, peer-reviewed journals.
This includes publications resulting from collaborations
between registries, such as a recent paper from the UK,
Germany and Dutch groups [18].
Registry characteristics
Characteristics of these registries composition are sum-
marised in Table 3.
The majority of the registries surveyed have national
coverage; two (Myotonic Dystrophy Family Registry –
USA and the Egyptian neuromuscular registry) accept
international registrations. Ten (46%) of the registries sur-
veyed are myotonic dystrophy specific while the others are
collecting information on all neuromuscular diseases or a
selection of other conditions (i.e. USA and Poland).
Resources and technical solutions
Our survey indicated that there is no coordinated or central
funding for DM patient registries. Funding is typically ob-
tained on a national level and is often a combination of
patient organisations or other charitable funding alongside
grant or project funding. One registry receives some
funding from industry (Canadian Neuromuscular Disease
Registry) in addition to other sources, while six (Australia,
BNMDR, China, CRAMP, Egypt, and Italy) receive funds
from the healthcare system or government.
The financial resources required to set up and main-
tain the registries were not provided in all cases. From
the information available the best-resourced registry is
the Japanese registry of muscular dystrophy (REMUDY)
with set up costs of €420,000; this is followed but the
Canadian Neuromuscular Disease Registry (CNDR with
Fig. 2 The registry purpose ranked from most to least importance by registry owners
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set up costs of €240,000 ($337,000 CAD) and annual
running costs of €250,000 ($350,000 CAD). Notably both
registries collect information from a range of neuromuscu-
lar diseases and these resources are not dedicated to myo-
tonic dystrophy. At the other end of the scale, there is the
Bulgarian Myotonic Dystrophy Registry, which has received
no funding and is managed through free donation of the
team’s time. A number of other registries have received
funding to set up the registry but this has not been sus-
tained and they are now running on limited or no funds.
Not considering these outliers, the mean set up cost was
€53,100 (range €1000 – € 145,000) and the annual running
costs €200 to €145,000 with a mean of €49,711.55.
This diversity in funding is reflected in the data cap-
ture methods implemented with no two registries using
the same IT solutions, and some using hard copy data
collection methods. The electronic solutions vary from
excel spreadsheets to complex custom software systems.
Data entry
Data is most often updated annually, with most registries
striving for annual updates though some stating this is
not always possible due to resource limitations. A number
of registries (Ukraine and Egypt) update details on a
six-monthly basis.
All but one of the surveyed registries involves data
entry by a clinician or another healthcare professional.
Only the Myotonic Dystrophy Family Registry (USA) is
entirely patient reported. However, an element of patient
reported data is included in seven additional registries
(UK, Italy, and USA National Registry at the University of
Rochester, Japan, Germany, New Zealand and Ukraine).
Several registries (DM-Scope and Australian DM registry)
also allow data entry from the diagnostic laboratory.
Alternative cohorts
Throughout this process it has been acknowledged that
there are many additional cohorts with valuable data on
myotonic dystrophy patients; this includes data being
collected in natural history studies, clinical trials and by
patient organisations and mailing lists. Two of the most
significant of these so-called “alternative” cohorts, are
held by the myotonic dystrophy support group (MDSG)
in the UK and the Muscular Dystrophy Association (MDA)
in the USA. MDSG collects contact details of families
in the UK, this is allows them to provide a quarterly
newsletter and act as a central point for of information
and support. There are currently more than 2500 families
registered with MDSG, this database does not contain clin-
ical or symptomatic details. MDA holds information on
over 10,500 people with a diagnosis of myotonic dystrophy
(DM1 and DM2), the majority of whom are adults. Devel-
oped initially as contact databases, these therefore does
not collect the Naarden dataset, however they capture a
number of socio economic items (insurance coverage,
employment status, income range and marital status) rele-
vant for analysis. These cohorts share challenges with the
more traditional registries in terms of resources to ensure
data quality and governance.
Discussion
Patient Registries are a key concern for all those involved
in the rare diseases field, however only about a fifth of rare
diseases have registries [19]. DM is one of these rare dis-
eases with a clear interest and investment in registries.
These registries represent over 10,000 DM patients which
represents a promising resource to support trial readiness
aims such as feasibility and recruitment and the import-
ance of cross international boundaries in this topic. This
overview presents a summary of the global infrastructure
currently available for DM and highlights points of agree-
ment between different registries and caveats that can be
improved to allow efficient future collaborations.
Utility and proliferation of the “Naarden Dataset”
Despite the variability seen across registries, in set-up,
purpose and execution many of the items of the original
dataset remain relatively consistent across resources.
The impact can be seen in the number of new registries
(66%) having adopted all of the mandatory items since
2009, compared to the 28% of registries that collected
these items prior to the Naarden workshop. The fact
that there was no agreement on items to be removed or
added suggests that the “Naarden” dataset may still be
an appropriate minimal dataset for myotonic dystrophy
patient registries. It is important to note that there is sig-
nificant number of registries not yet collecting all items
of the core dataset. This may reflect the variety of re-
sources available to the registries. However, it may also
indicate a need to increase awareness of the dataset and
to better highlight the added value to of collecting this
data in a harmonised way. Yet, with many registries col-
lecting items beyond the previously agreed dataset an
expansion of the dataset could be considered, in particu-
lar the addition of anthropometric measurements and
items looking at cognitive impairment. Furthermore, the
higher frequency of DM2 patients in some areas of cen-
tral Europe may also call for an adapted dataset account-
ing for differences in phenotypic presentation. With
more patients entering clinical trials over the coming
years, this should be captured in additional questions.
The growing number of registries collecting additional
patient reported outcomes also calls for further consider-
ation. A significant amount of work has already been done
towards the selection and harmonisation of disease-specific
reported outcomes by the Outcome Measures for Myotonic
Dystrophy initiative (OMMYD) [20, 21]. The registry com-
munity should consider adopting these guidelines to ensure
Wood et al. Orphanet Journal of Rare Diseases  (2018) 13:155 Page 8 of 11
only tools validated in these disease areas are included. We
also recognise the importance of including patient repre-
sentation when refining the outcomes most appropriate to
include in registries.
The numbers of research studies and publications de-
rived from the registries demonstrate the utility of the
registries. This is best demonstrated in the multicentre
clinical trial setting of OPTIMISTIC [22], in which the regis-
tries from the UK, France, Germany and the Netherlands
were successfully used for feasibility and recruitment.
This experience together with tools already developed
by TREAT-NMD mean that the myotonic dystrophy
registry community is well placed to help facilitate and
accelerate clinical research.
Future harmonisation and interoperability
There is a clear need for a more integrated approach to
DM registries; however, the building blocks for increased
collaboration are in place. The registries identified, share
common data items and have the same fundamental
purpose. All of the registries we contacted were open to
the idea of increased collaboration. However, the diver-
sity in registry collection methods may present a bottle-
neck when looking to future interpretability. As part of a
recent collaboration between three of these registries
surveying about falls and related injuries, minor differ-
ences between collected demographic data limited the
full interpretability of the results from the questionnaire
[18]. Within the wider rare disease registry community
there is a call for more standardised collection of data
using ontologies and for data to be meet the FAIR (Find-
able, accessible, interoperable and reusable) data principles
[23, 24]. Interoperability of these datasets could also be
addressed through a common identifier, or privacy protec-
tion record linkage (PPRL). The myotonic dystrophy com-
munity is well placed to be part of these developments.
Some investment would be required in order for the
existing registries to meet these standards; however, a
significant amount of work in this area is being carried
out in some larger projects such as RD-Connect [25],
who are looking to demonstrate how different datasets
including registries can be linked. Beyond connecting
registries with each other, increased value could come
from further linking registry data to biobanks, natural
history and omics data for example. Furthermore, these
larger initiatives should be utilised to increase the visibil-
ity of these registries, for example, currently a search of
the Orphanet catalogue of rare disease registries listed
only 9 DM registries while the RD-Connect Registry and
Biobank Finder system returns 13 results.
It would be unrealistic to expect that a single individ-
ual or group will fully lead the establishment of a global
and unique rare-disease registry. Patient registries are
dependent on the availability of resources (human and
technology), standards of care and research and specific
regulatory bodies or criteria [1, 4, 26]. However, this re-
port can be considered a rare disease case-study about
the success of collaborating at a global level and the im-
portance of establishing a set of data considered essen-
tial for a disease-specific patient registry.
Conclusion
In conclusion, there is a desire within the myotonic dys-
trophy community to better unite the registry landscape
and increase interoperability. Consideration will have to be
given to the resources available for this to ensure sustain-
ability. In addition, it is important to see how these regis-
tries fit in the bigger picture of the rare disease community.
The registries contacted are eager to increase and continue
this collaboration, a follow-up workshop might be required
to work towards meeting the goals of standardisation and
interpretability. Such a workshop could also be used to bet-
ter address the impact of the data set in the current trial
landscape. The networks provided by TREAT-NMD,
RD-Connect, and the International Rare Diseases Research
Consortium (IRDiRC) represent access to the necessary
tools and stakeholders to ensure the greatest impact of
these valuable resources. The utility could be further dem-
onstrated through analysis of the data within all of these
registries. Analysis on the 10,000 patients would provide an
insight into this condition on a scale not previously seen.
Highlights
 Disease-specific Patient Registries are indispensable
platforms to succeed with therapeutic solutions.
 Over 10,000 myotonic dystrophy patients captured
in registries worldwide.
 Twenty-two registries collect a comparable dataset
on myotonic dystrophy patients.
 There is still a huge variety in data collection and
funding mechanisms among registries.
 Significant clinical research has been supported by
these myotonic dystrophy registries.
Additional file
Additional file 1: Survey to capture details about the registry, database
or mailing list. (PDF 270 kb)
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